BlackRock
BOLT icon

BlackRock’s Bolt Biotherapeutics BOLT Stock Holding History

BlackRock’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4K Hold
9,711
– – ﹤0.01% 5245
2026
Q1 		$39.2K Hold
9,711
– – ﹤0.01% 5184
2025
Q4 		$53.1K Hold
9,711
– – ﹤0.01% 5041
2025
Q3 		$51.7K Sell
9,711
-839
-8% -$4.65K ﹤0.01% 4978
2025
Q2 		$60.9K Sell
10,550
-2,882
-21% -$19.1K ﹤0.01% 4954
2025
Q1 		$107K Sell
13,432
-73
-0.5% -$702 ﹤0.01% 4752
2024
Q4 		$145K Buy
13,505
+25
+0.2% +$302 ﹤0.01% 4687
2024
Q3 		$175K Buy
13,480
+127
+1% +$1.75K ﹤0.01% 4558
2024
Q2 		$200K Buy
13,353
+605
+5% +$11.9K ﹤0.01% 4548
2024
Q1 		$357K Sell
12,748
-116
-0.9% -$2.69K ﹤0.01% 4464
2023
Q4 		$288K Sell
12,864
-37
-0.3% -$720 ﹤0.01% 4550
2023
Q3 		$268K Sell
12,901
-1,494
-10% -$36.5K ﹤0.01% 4596
2023
Q2 		$369K Buy
14,395
+673
+5% +$21.4K ﹤0.01% 4574
2023
Q1 		$381K Buy
13,722
+66
+0.5% +$1.93K ﹤0.01% 4602
2022
Q4 		$355K Sell
13,656
-8,504
-38% -$233K ﹤0.01% 4698
2022
Q3 		$657K Sell
22,160
-357
-2% -$14.8K ﹤0.01% 4634
2022
Q2 		$918K Sell
22,517
-58,102
-72% -$2.26M ﹤0.01% 4565
2022
Q1 		$4.42M Sell
80,619
-1,816
-2% -$122K ﹤0.01% 4033
2021
Q4 		$8.08M Buy
82,435
+9,709
+13% +$1.84M ﹤0.01% 3787
2021
Q3 		$18.4M Buy
72,726
+25,633
+54% +$7.24M ﹤0.01% 3334
2021
Q2 		$14.6M Buy
47,093
+5,134
+12% +$2.08M ﹤0.01% 3481
2021
Q1 		$27.6M Buy
+41,959
New +$27.3M ﹤0.01% 3000

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock's BOLT Position: Q2 2026 in Review

BlackRock held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 9,711 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5245.

BlackRock first reported a position in BOLT in Q1 2021 and has held it in 22 quarters since. The position peaked at $27.6M in Q1 2021. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • BlackRock held 9,711 shares of Bolt Biotherapeutics worth $37.4K as of Q2 2026.
  • BlackRock left its Bolt Biotherapeutics share count unchanged in Q2 2026.
  • Bolt Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5245 holding.
  • BlackRock first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
  • BlackRock's Bolt Biotherapeutics position peaked at $27.6M in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.